Known as a pioneer in Asia’s women’s and fetal health industry, Singapore-based diagnostics developer, INEX Innovate has obtained a CE mark for its lead ovarian cancer product, the OvaCis® Rapid Test. Slated to launch in the EU and Southeast Asian markets by the end of 2022, OvaCis® is a first of its kind point-of-care (POCT) test that discriminates benign from malignant ovarian cysts in an operating theatre setting. A previous iteration of OvaCis® was launched in 2019, and the latest improvements now mean an extension of the product’s shelf life to a minimum of 18 months at room temperature storage. This makes it convenient to store the kits in a primary healthcare setting.
The current standard of practice for ovarian cancer screening, called frozen section, increases the surgical procedure time by up to 60 minutes, consequently increasing the risk of infections and anaesthesia. Frozen section is also dependent on the skill of the pathologist conducting the biopsy sections, thus ovarian cancers (especially early ovarian cancers) can be missed.
OvaCis® Rapid Test works by identifying a protein biomarker (haptoglobin) evenly distributed in ovarian cysts fluid to determine if the cysts are benign or malignant. The test was developed as a rapid test format, and has proved to be user friendly requiring only minimal training and 5 minutes of hands-on time. Read more here.